Key result
Adjuvant therapy for osteogenic sarcoma represents a milestone in treatment and holds promise for managing other refractory tumors.
Answers are grounded in this paper and cite their sources.
The editorial highlights the promising preliminary results of adjuvant therapy for osteogenic sarcoma, suggesting potential implications for other refractory tumors.
The two papers published in this issue of the Journal detailing the excellent preliminary results in the adjuvant therapy of osteogenic sarcoma not only represent a milestone in the treatment of this disease but also hold great promise for the future management of some other more common types of refractory tumors. For many years osteogenic sarcoma has been the "bête noire" of the chemotherapist, in that although the progress of the pulmonary metastases could be carefully followed by chest films, they rarely showed appreciable response to any chemotherapeutic agent. In refractoriness to chemotherapy, osteogenic sarcoma closely approximates the adult tumors . . .
No takes yet. Share an insight, caveat, or question.
Joseph H. Burchenal (1974) conducted an editorial in Osteogenic sarcoma. Adjuvant therapy was evaluated. Adjuvant therapy for osteogenic sarcoma represents a milestone in treatment and holds promise for managing other refractory tumors.
Synapse has enriched 10 related papers. Consider them for comparative context: